Lyell Immunopharma, Inc. (LYEL) vs Pyxis Oncology, Inc. (PYXS)
Lyell Immunopharma, Inc. and Pyxis Oncology, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and Pyxis Oncology, Inc. are of similar size ($250.2M and $248.0M). Pyxis Oncology, Inc. has the higher net margin (0.00% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 13 metrics below, Pyxis Oncology, Inc. leads on 7 and Lyell Immunopharma, Inc. on 6.
Valuation
Profitability
| Metric | LYEL | PYXS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 65.16% |
| Operating margin | (949,981.48%) | 0.00% | 0.00% |
| Net margin | (920,285.19%) | 0.00% | 0.00% |
| Free cash flow margin | (647,681.48%) | 0.00% | 0.00% |
| Return on equity | (93.28%) | (179.10%) | (57.72%) |
| Return on assets | (71.34%) | (99.62%) | (49.22%) |
| Return on invested capital | (539.53%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack